Skip to main content

Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    Health Outcome(s)
    emergency use authorization (EUA) utilization

    The objective of this request was to identify patients of all ages with evidence of baricitinib or tocilizumab use in the hospital setting, with and without a COVID-19 diagnosis and/or COVID-19 positive lab. We also assessed evidence of concomitant use of remdesivir with baricitinib and systemic corticosteroids with tocilizumab.

    The study period includes data from April 1, 2020 to March 31, 2021. We distributed this request to 22 National Patient-Centered Clinical Research Network (PCORnet) DataMarts on September 21, 2021.

    Additional Details
    FDA Center
    Time Period
    April 1, 2020 - March 31, 2021
    Analysis Type
    PCORnet Descriptive Analysis
    Population / Cohort
    All individuals
    Data Sources
    National Patient-Centered Clinical Research Network (PCORnet)